<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347228</url>
  </required_header>
  <id_info>
    <org_study_id>OB318CLCT01</org_study_id>
    <nct_id>NCT02347228</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oneness Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oneness Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this Phase I study are to determine the maximum tolerable dose (MTD) and to&#xD;
      evaluate pharmacokinetics (PK), safety/ tolerability and preliminary efficacy of OB318 in&#xD;
      patients with advanced solid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) of OB318</measure>
    <time_frame>28 days</time_frame>
    <description>NOTE: DLT is defined as any grade 3 or above toxicity by NCI-CTCAE version 4.03, as determined by the investigator and sponsor, to be at least possibly related in causality to the administered investigational product OB318 and will be observed during the 4 weeks of treatment for patients in the dose escalation phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of OB318</measure>
    <time_frame>28 days</time_frame>
    <description>NOTE:- MTD is defined as the prior dose level below the dose level at which 2/3 or 2/6 subjects suffer dose limiting toxicity (DLT) in the dose escalation phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory safety tests (hematology, biochemistry, urinalysis) from baseline</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Laboratory safety tests will be performed at screening, baseline, Day 14 and Day 28 for the dose escalation, and at the last follow-up visit. For the extension phase, lab tests will be done before each 28 days cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse events (SAEs)</measure>
    <time_frame>up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities ≥ grade 3, according to NCI-CTCAE version 4.03, related to OB318, during extension phase</measure>
    <time_frame>up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of toxicities ≥ grade 3, according to NCI-CTCAE version 4.03, related to OB318, during extension phase</measure>
    <time_frame>up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical examination from baseline</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Physical examination will be performed at screening, baseline, and Day 28 for the dose escalation, and at the last follow-up visit. For the extension phase, physical examination will be done at last day of each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs from baseline</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Vital signs will be performed at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Electrocardiogram (ECG) results (QRS, QT, QTc, RR intervals)</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Electrocardiogram (ECG) is conducted at screening, baseline, Day 14 and Day 28 for the dose escalation, and at the last follow-up visit. For the extension phase, ECG will be conducted at the same time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at the end of the</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Imaging for tumor assessment will be made at screening, at the end of the treatment for the dose escalation and at the end of Cycle 2 for the extension phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Cmax</measure>
    <time_frame>Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- AUC from time zero to the last quantifiable concentration</measure>
    <time_frame>Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- AUC from time zero extrapolated to infinity</measure>
    <time_frame>Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters-CL/F</measure>
    <time_frame>Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters-Vz/F</measure>
    <time_frame>Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters-Tmax</measure>
    <time_frame>Day 1 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Terminal elimination half-life</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Terminal elimination rate constant</measure>
    <time_frame>Day 1 and Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters-Ctrough</measure>
    <time_frame>Day 27 and Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318 ; Day 7 and Day 14 of Cycle additionally for dose level 1 only</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Cmin,ss</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Cmax,ss</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Cavg,ss</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- AUC(0-24h)</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- CLss/F</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Vz,ss/F</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Tmax,ss</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- FI</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters- Rac</measure>
    <time_frame>Day 28 of Cycle 1 from the subjects with dose level 1, 2, 4, 6, 8, and 10 of OB318</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>OB318 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OB318 capsule</intervention_name>
    <description>Oral qd, at least 30 minutes before breakfast</description>
    <arm_group_label>OB318 capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients of age ≥20 years&#xD;
&#xD;
          2. Pathologically or cytologically confirmed advanced solid tumors for which standard&#xD;
             therapy proven to provide clinical benefit does not exist or is no longer effective;&#xD;
             the diagnosis of hepatocellular carcinoma (HCC) made according to the imaging&#xD;
             specified in the American Association for the Study of Liver Diseases (AASLD) 2018 is&#xD;
             acceptable.&#xD;
&#xD;
          3. Evaluable disease, either at least one measurable untreated target lesion on imaging&#xD;
             by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria or measurable by&#xD;
             informative tumor marker(s).&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2.&#xD;
&#xD;
          5. Life expectancy ≥ 3 months.&#xD;
&#xD;
          6. If history of brain metastases treated with radiation therapy, radiation therapy is&#xD;
             required to be completed at least 3 months prior to enrolment and metastasis achieve&#xD;
             stable disease (SD) since radiation completion.&#xD;
&#xD;
          7. Must have recovered from toxicities of previous anti-cancer treatments to NCI-CTCAE&#xD;
             grade 1 or lower, except for alopecia.&#xD;
&#xD;
          8. Laboratory values at screening of:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500 /mm3;&#xD;
&#xD;
               -  Platelets ≥ 75,000 /mm3;&#xD;
&#xD;
               -  Hemoglobin (Hb) ≥ 8.5 g/dL;&#xD;
&#xD;
               -  Total bilirubin ≤2.0 mg/dL;&#xD;
&#xD;
               -  AST (SGOT) ≤ 3 × ULN (upper limit of normal);&#xD;
&#xD;
               -  ALT (SGPT) ≤ 3 × ULN;&#xD;
&#xD;
               -  Serum creatinine ≤1.5 mg/dL or a measured creatinine clearance ≥ 60 mL/min.&#xD;
&#xD;
          9. Patients with primary liver cancer or hepatic metastasis are eligible to enroll,&#xD;
             provided that, at screening, the following criteria are met:&#xD;
&#xD;
               -  Total bilirubin ≤2.0 mg/dL;&#xD;
&#xD;
               -  AST and ALT ≤ 5 × ULN;&#xD;
&#xD;
               -  Child-Pugh Class A;&#xD;
&#xD;
               -  Patients with a history of esophageal bleeding have varices that have been&#xD;
                  sclerosed or banded and no bleeding episodes have occurred during the prior 6&#xD;
                  months.&#xD;
&#xD;
         10. Female patients must be either of non-childbearing potential, i.e. surgically&#xD;
             sterilized or one year post-menopausal; or, if of childbearing potential, confirmed&#xD;
             not pregnant at screening and must use adequate contraceptive precautions (as per&#xD;
             investigator) during the entire treatment period of this study and for 6 months after&#xD;
             exiting from the study.&#xD;
&#xD;
         11. Male patients with female partners of childbearing potential must be willing to use a&#xD;
             reliable form of contraception (as per investigator), from screening until 6 months&#xD;
             after exiting from the study.&#xD;
&#xD;
         12. Given signed and dated written informed consent and willing/able to comply with all&#xD;
             protocol required visits/procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primary major surgery &lt; 4 weeks prior to the planned first study treatment day.&#xD;
&#xD;
          2. Lactating or pregnant women or plans to be become pregnant.&#xD;
&#xD;
          3. Except for alopecia, any drug-related AE from any previous treatments not recovered to&#xD;
             grade 1 or less prior to the planned first study treatment day.&#xD;
&#xD;
          4. With active systemic infections, active and clinically significant cardiac diseases,&#xD;
             active gastrointestinal diseases, active pulmonary diseases, or medical conditions&#xD;
             that may significantly affect adequate absorption of investigational product, eg., bad&#xD;
             nutrition, proteinuria, etc..&#xD;
&#xD;
          5. Previous malignancy, except for basal-cell carcinoma of skin or carcinoma-in-situ of&#xD;
             the uterine cervix, unless the tumor was treated with curative intent more than 2&#xD;
             years prior to study entry.&#xD;
&#xD;
          6. Known allergic to OB318 or its formulation excipients.&#xD;
&#xD;
          7. History of autoimmune disease.&#xD;
&#xD;
          8. Taking anti-coagulant or anti-platelet drugs (eg aspirin, Coumadin, ginko,&#xD;
             clopidogrel).&#xD;
&#xD;
          9. Use of any investigational agents or non-registered product within 4 weeks of&#xD;
             baseline.&#xD;
&#xD;
         10. Known human immunodeficiency virus (HIV) positivity.&#xD;
&#xD;
         11. With conditions, judged by the investigator, as unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Liang Ho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ciao Hong</last_name>
    <phone>+886-2-2703-1098</phone>
    <phone_ext>361</phone_ext>
    <email>Ciao.Hong@onenessbio.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Liang</last_name>
    <phone>+886-2-2703-1098</phone>
    <phone_ext>366</phone_ext>
    <email>Lisa.Liang@onenessbio.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Liang Ho</last_name>
      <phone>02-8792-3311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang Ho Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Hong Cheng</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 25, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OB318</keyword>
  <keyword>Advanced Solid Malignancies</keyword>
  <keyword>Antrodia cinnamomea</keyword>
  <keyword>Antrodia camphorata</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

